These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9796663)

  • 1. Viral findings during febrile episodes after cytotoxic chemotherapy in patients with hematological malignancies.
    Rintala EM; Nikoskelainen J; Ziegler T; Jussila R
    Eur J Clin Microbiol Infect Dis; 1998 Aug; 17(8):593-4. PubMed ID: 9796663
    [No Abstract]   [Full Text] [Related]  

  • 2. Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran.
    Sheikhbahaei S; Mohammadi A; Sherkat R; Naeini AE; Yaran M; Najafi S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(3):302-307. PubMed ID: 30747087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia.
    Gatt ME; Strahilevitz J; Sharon N; Lavie D; Goldschmidt N; Kalish Y; Gural A; Paltiel OB
    Integr Cancer Ther; 2015 Sep; 14(5):428-35. PubMed ID: 26036623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fever profile of febrile neutropenia in patients treated with cancer chemotherapy for hematological malignancies].
    Tamai Y; Imataki O; Kawakami K
    Gan To Kagaku Ryoho; 2010 May; 37(5):859-62. PubMed ID: 20495316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy in elderly patients with hematological malignancies].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1586-90. PubMed ID: 21996952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feasibility of early discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cordonnier C
    Haematologica; 2006 Feb; 91(2):150a. PubMed ID: 16461296
    [No Abstract]   [Full Text] [Related]  

  • 7. The challenges and perspectives in treating adolescent and young adult patients with hematological malignancies.
    Raanani P; Tallman MS
    Acta Haematol; 2014; 132(3-4):263. PubMed ID: 25228550
    [No Abstract]   [Full Text] [Related]  

  • 8. New and emerging drug targets for the treatment of hematological malignancies.
    Bendall LJ
    Curr Drug Targets; 2010 Jul; 11(7):767-8. PubMed ID: 20370651
    [No Abstract]   [Full Text] [Related]  

  • 9. New perspectives in the treatment of hematological malignancies.
    Kizaki M
    Curr Pharm Biotechnol; 2006 Oct; 7(5):313. PubMed ID: 17076646
    [No Abstract]   [Full Text] [Related]  

  • 10. Footwear exchange has no influence on the incidence of febrile neutropenia in patients undergoing chemotherapy for hematologic malignancies.
    Sugahara H; Mizuki M; Matsumae S; Nabetani Y; Kikuchi M; Kanakura Y
    Infect Control Hosp Epidemiol; 2004 Jan; 25(1):51-4. PubMed ID: 14756220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial agent prescription patterns for chemotherapy-induced febrile neutropenia in patients with hematological malignancies at Sultan Qaboos University Hospital, Oman.
    Al Balushi KA; Balkhair A; Ali BH; Al Rawas N
    J Infect Public Health; 2013 Jun; 6(3):216-21. PubMed ID: 23668467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.
    Hasselbalch HC
    Curr Drug Targets; 2011 Mar; 12(3):387-91. PubMed ID: 21143152
    [No Abstract]   [Full Text] [Related]  

  • 13. Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies.
    Shinohara A; Yoshiki Y; Masamoto Y; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Lymphoma; 2013 Apr; 54(4):794-8. PubMed ID: 22978686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
    Lin HC; Yang YS; Teng CJ; Shen CH; Jan YG; Cheng SB; Wu CC; Lin YL; Huang CC; P'eng FK
    World J Surg Oncol; 2017 Nov; 15(1):194. PubMed ID: 29096656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gastrointestinal tract is a common target of invasive aspergillosis in patients receiving cytotoxic chemotherapy for hematological malignancy.
    Kami M; Hori A; Takaue Y; Mutou Y
    Clin Infect Dis; 2002 Jul; 35(1):105-6; author reply 106-7. PubMed ID: 12060886
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice.
    Ma H; Mallampati S; An G; Wang J
    Biomed Res Int; 2015; 2015():157570. PubMed ID: 26436085
    [No Abstract]   [Full Text] [Related]  

  • 18. Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients.
    Rapoport BL; Uys A
    Chemotherapy; 2008; 54(2):117-9. PubMed ID: 18303260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the effects of treatments for hematological malignancies on prepubertal growth.
    Pearce MS
    Pediatr Hematol Oncol; 2000 Sep; 17(6):441-3. PubMed ID: 10989463
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigational antibody-drug conjugates for hematological malignancies.
    Polson AG; Ho WY; Ramakrishnan V
    Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.